UNSPSC 51362602: Gabapentin enacarbil

This classification denotes a sedative and hypnotic with the molecular formula C16H27NO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 75OCL1SPBQ chemically known as cyclohexaneacetic acid, 1-((((1-(2-methyl-1-oxopropoxy)ethoxy)carbonyl)amino)methyl)- but generally known as gabapentin enacarbil, which bears US NIH Compound Identifier 9883933. European Medicines Agency schedules Gabapentin enacarbil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB35115.

UNSPSC 51362602 Gabapentin enacarbil is a Commodity code that nominally identifies a specific pharmaceutical product, but recent state and local solicitations tagged under this code do not reflect procurement of gabapentin enacarbil itself. Instead, the code appears in opportunities soliciting naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer pharmacy benefit program capabilities (Texas Health and Human Services Commission), and generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing (Minnesota Multistate Cooperative Purchasing Alliance). The mismatch between the code's narrow pharmaceutical name and the actual scope of opportunities suggests this code sees limited relevant activity or misclassification in state and local procurement systems. When pharmaceutical procurement does occur under or near this code, it spans state health departments, county health systems, and multistate cooperative purchasing alliances acquiring drugs, medical countermeasures, and pharmacy benefit program services for community health, emergency preparedness, and employee health plan populations.

Recent activity centers on Florida, Texas, and Minnesota. Seminole County's IFB (60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county's community health building, including shipping and delivery costs in vendor pricing. The Texas Health and Human Services Commission issued an RFI (HHS0017013, April 3, 2026) to explore direct-to-manufacturer prescription programs for pharmacy benefit management, a market-intelligence phase preceding formal solicitation. The Minnesota Department of Administration, through MMCAP, posted an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across state and participating local facilities including Oregon, requiring NDC-specific pricing, cGMP and DSCSA compliance, relationships with authorized wholesalers, and a 3 percent administrative fee. The code shows episodic rather than concentrated activity; no standout repeat buyers or set-aside designations appear in recent notices.